Pictet Biotech P Dist GBP
Overview
| Fund manager's initial charge | 5.00% |
|---|---|
| HL initial saving | 5.00% |
| Net initial charge | 0.00% |
| Dealing charge | Free |
| Fund manager's annual charge | 1.60% |
| Performance charges | No |
| Total Expense Ratio | 2.01% |
| HL annual saving | 0.00% 2 |
| Platform fee | Free |
| Launch date | 01-12-1995 |
| Launch price | $67.19 |
| Sector | Offshore |
| Fund size | $1,057 million |
| Number of holdings | 46 |
| Fund type | SICAV |
| Type of units | Income |
Please read the Simplified Prospectus/Key Investor Information Document in addition to the information above.
Invest online now
Before you invest please read the key features and Simplified Prospectus/Key Investor Information Document for more details.
HL research - our view on this fund
About the Fund Manager
Michael Sjöström
Located in: Montreal
Michael Sjöström, CFA, is the founder and Chief Investment Officer of Sectoral Asset Management which he founded in October 2000. He is the Senior Fund Manager for the Pictet Biotech fund since its inception. Prior to founding Sectoral Asset Management, Michael worked for 8 years at Pictet & Cie as Deputy Head of the Swiss Research Team and as a financial analyst covering the pharmaceutical and biotechnology sectors in Switzerland and Europe. Michael was also Head of the Global Pharmaceutical Research team. Prior to joining Pictet, Michael spent 3 years at Bordier & Cie covering Swiss equities and managing Swiss equity portfolios. Michael obtained a BA degree from the St. Gallen School of Economics, Business and Public Administration and Law (HSG) with a specialisation in Financial Management and Controlling. Michael is also a Chartered Financial Analyst (CFA) and a founding member of the Swiss Society of Investment Professionals, part of the Association for Investment Management and Research.
Income details
| Running yield | N/a |
|---|---|
| Income paid | Annually |
| Type of payment | No income |
All yields are variable and not guaranteed. There is currently no yield information available for this fund.
Distribution dates
| Ex-dividend date | 02 December 2012 |
|---|---|
| Payment date 4 | 03 December 2012 |
Top 10 holdings
| Amgen | 6.33% |
|---|---|
| InterMune | 6.00% |
| Novo Nordisk A/S B | 5.07% |
| Biogen Idec | 5.03% |
| Celgene Corp. | 4.84% |
| Onyx Pharmaceuticals | 4.67% |
| BioMarin Pharmaceutical | 4.67% |
| Ariad Pharmaceuticals | 4.50% |
| Pharmasset | 4.50% |
| Algeta ASA | 4.40% |
Top 10 sectors
| Pharmaceuticals & Biotechnology | 99.75% |
|---|---|
| Non-Classified | 0.25% |
| Cash and Equiv. | -0.00% |
Top 10 countries
| United States | 82.68% |
|---|---|
| Denmark | 5.07% |
| Norway | 4.40% |
| Switzerland | 4.20% |
| United Kingdom | 2.14% |
| Sweden | 1.25% |
| Non-Classified | 0.25% |
| Cash and Equiv. | -0.00% |
Some of the data on this page and other related pages is provided to you for your information and is received from the Fund Management Company administering this fund. Hargreaves Lansdown accepts no liability for the reliability or accuracy of the data provided by third parties.
2 Annual saving is not available in the SIPP or Junior ISA.
4 If you elect to receive the income from a Vantage ISA, Fund or Share Account, we will collect any dividends for you and then pay them directly into your bank account within the first 10 working days of the following month.
Prices as at 09-02-2012. Data as at 31/08/2011.
